B‐cell lymphoma, unclassifiable, with features intermediate between diffuse large B‐cell lymphoma and burkitt lymphoma: study of 39 cases
Summary B‐cell lymphoma, unclassifiable (B‐UCL), with features intermediate between diffuse large B‐cell lymphoma and Burkitt lymphoma, is a poorly characterized entity. Therefore, we investigated cases of B‐UCL treated by the Nebraska Lymphoma Study Group (NLSG). We searched the NLSG registry for y...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2013-07, Vol.162 (1), p.40-49 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 49 |
|---|---|
| container_issue | 1 |
| container_start_page | 40 |
| container_title | British journal of haematology |
| container_volume | 162 |
| creator | Perry, Anamarija M. Crockett, David Dave, Bhavana J. Althof, Pamela Winkler, Lisa Smith, Lynette M. Aoun, Patricia Chan, Wing C. Fu, Kai Greiner, Timothy C. Bierman, Phillip Gregory Bociek, Robert Vose, Julie M. Armitage, James O. Weisenburger, Dennis D. |
| description | Summary
B‐cell lymphoma, unclassifiable (B‐UCL), with features intermediate between diffuse large B‐cell lymphoma and Burkitt lymphoma, is a poorly characterized entity. Therefore, we investigated cases of B‐UCL treated by the Nebraska Lymphoma Study Group (NLSG). We searched the NLSG registry for years 1985–2010 for cases of B‐UCL. Immunohistochemical stains and fluorescence in situ hybridization studies for MYC, BCL2 and BCL6 gene rearrangements were performed. Among the 39 cases studied, 54% were male and 46% were female, with a median age of 69 years. The majority of patients presented with advanced‐stage disease (62%) and had high (3–5) International Prognostic Index (IPI) scores (54%). The median overall survival (OS) was only 9 months and the 5‐year OS was 30%. Patients with low IPI scores (0–2) had a better survival than those with high scores (3–5). The cases were genetically heterogeneous and included 11 ‘double‐hit’ lymphomas with rearrangements of both MYC and BCL2 or BCL6. None of the immunohistochemical or genetic features was predictive of survival. This B‐cell lymphoma is a morphologically‐recognizable entity with a spectrum of genetic abnormalities. New and better treatments are needed for this aggressive lymphoma. |
| doi_str_mv | 10.1111/bjh.12343 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1399916701</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1367879445</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4233-3764c85be43aa9b0b6a497f6b9793646370ae22f7bca4f307e0948aceee6e9f13</originalsourceid><addsrcrecordid>eNqN0cFqFDEYB_BQlHZbPfQFSi6CQqdNJtlk480WtUrBi56HL9kvbtrMzDbJsOzNFxD6jD6Js-62HqRgLoHkx_8L-RNyzNkZH9e5vVmc8VpIsUcmXKhpVXPJn5EJY0xXnMnZATnM-YYxLtiU75ODWqjxiqsJ-Xnx68e9wxhpXLfLRd_CKR06FyHn4APYiKd0FcqCeoQyJMw0dAVTi_MABanFskLs6Dx4P2SkEdJ3pP9kUujm1A7pNpTyePiW5jLM17T3VBjqIGN-QZ57iBlf7vYj8u3D-6-XV9X1l4-fLt9dV07WQlRCK-lmU4tSABjLrAJptFfWaCOUVEIzwLr22jqQXjCNzMgZOERUaDwXR-T1NneZ-rsBc2nakDcvhg77ITdcGGO40ux_qNIzbaScjvTNlrrU55zQN8sUWkjrhrNmU1QzFtX8KWq0J7vYwY6f-SgfmhnBqx2A7CD6BJ0L-a_TUhnBNu5861Yh4vrpic3F56vt6N8lAqx7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1367879445</pqid></control><display><type>article</type><title>B‐cell lymphoma, unclassifiable, with features intermediate between diffuse large B‐cell lymphoma and burkitt lymphoma: study of 39 cases</title><source>MEDLINE</source><source>Wiley Journals</source><source>Wiley Online Library Free Content</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Perry, Anamarija M. ; Crockett, David ; Dave, Bhavana J. ; Althof, Pamela ; Winkler, Lisa ; Smith, Lynette M. ; Aoun, Patricia ; Chan, Wing C. ; Fu, Kai ; Greiner, Timothy C. ; Bierman, Phillip ; Gregory Bociek, Robert ; Vose, Julie M. ; Armitage, James O. ; Weisenburger, Dennis D.</creator><creatorcontrib>Perry, Anamarija M. ; Crockett, David ; Dave, Bhavana J. ; Althof, Pamela ; Winkler, Lisa ; Smith, Lynette M. ; Aoun, Patricia ; Chan, Wing C. ; Fu, Kai ; Greiner, Timothy C. ; Bierman, Phillip ; Gregory Bociek, Robert ; Vose, Julie M. ; Armitage, James O. ; Weisenburger, Dennis D.</creatorcontrib><description>Summary
B‐cell lymphoma, unclassifiable (B‐UCL), with features intermediate between diffuse large B‐cell lymphoma and Burkitt lymphoma, is a poorly characterized entity. Therefore, we investigated cases of B‐UCL treated by the Nebraska Lymphoma Study Group (NLSG). We searched the NLSG registry for years 1985–2010 for cases of B‐UCL. Immunohistochemical stains and fluorescence in situ hybridization studies for MYC, BCL2 and BCL6 gene rearrangements were performed. Among the 39 cases studied, 54% were male and 46% were female, with a median age of 69 years. The majority of patients presented with advanced‐stage disease (62%) and had high (3–5) International Prognostic Index (IPI) scores (54%). The median overall survival (OS) was only 9 months and the 5‐year OS was 30%. Patients with low IPI scores (0–2) had a better survival than those with high scores (3–5). The cases were genetically heterogeneous and included 11 ‘double‐hit’ lymphomas with rearrangements of both MYC and BCL2 or BCL6. None of the immunohistochemical or genetic features was predictive of survival. This B‐cell lymphoma is a morphologically‐recognizable entity with a spectrum of genetic abnormalities. New and better treatments are needed for this aggressive lymphoma.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.12343</identifier><identifier>PMID: 23600716</identifier><identifier>CODEN: BJHEAL</identifier><language>eng</language><publisher>Oxford: Blackwell</publisher><subject>Adult ; Aged ; BCL2 ; Biological and medical sciences ; Biomarkers, Tumor - genetics ; Biomarkers, Tumor - metabolism ; Burkitt lymphoma ; Burkitt Lymphoma - diagnosis ; Burkitt Lymphoma - therapy ; Combined Modality Therapy ; Cytogenetic Analysis ; Diagnosis, Differential ; diffuse large B‐cell lymphoma ; Female ; Hematologic and hematopoietic diseases ; Humans ; Immunophenotyping ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Lymphoma, B-Cell - classification ; Lymphoma, B-Cell - diagnosis ; Lymphoma, B-Cell - therapy ; Lymphoma, Large B-Cell, Diffuse - diagnosis ; Lymphoma, Large B-Cell, Diffuse - therapy ; Male ; Medical sciences ; Middle Aged ; MYC ; Neoplasm Staging ; Treatment Outcome ; Tumors ; unclassifiable B‐cell lymphoma</subject><ispartof>British journal of haematology, 2013-07, Vol.162 (1), p.40-49</ispartof><rights>2013 John Wiley & Sons Ltd</rights><rights>2014 INIST-CNRS</rights><rights>2013 John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4233-3764c85be43aa9b0b6a497f6b9793646370ae22f7bca4f307e0948aceee6e9f13</citedby><cites>FETCH-LOGICAL-c4233-3764c85be43aa9b0b6a497f6b9793646370ae22f7bca4f307e0948aceee6e9f13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjh.12343$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjh.12343$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27469306$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23600716$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Perry, Anamarija M.</creatorcontrib><creatorcontrib>Crockett, David</creatorcontrib><creatorcontrib>Dave, Bhavana J.</creatorcontrib><creatorcontrib>Althof, Pamela</creatorcontrib><creatorcontrib>Winkler, Lisa</creatorcontrib><creatorcontrib>Smith, Lynette M.</creatorcontrib><creatorcontrib>Aoun, Patricia</creatorcontrib><creatorcontrib>Chan, Wing C.</creatorcontrib><creatorcontrib>Fu, Kai</creatorcontrib><creatorcontrib>Greiner, Timothy C.</creatorcontrib><creatorcontrib>Bierman, Phillip</creatorcontrib><creatorcontrib>Gregory Bociek, Robert</creatorcontrib><creatorcontrib>Vose, Julie M.</creatorcontrib><creatorcontrib>Armitage, James O.</creatorcontrib><creatorcontrib>Weisenburger, Dennis D.</creatorcontrib><title>B‐cell lymphoma, unclassifiable, with features intermediate between diffuse large B‐cell lymphoma and burkitt lymphoma: study of 39 cases</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Summary
B‐cell lymphoma, unclassifiable (B‐UCL), with features intermediate between diffuse large B‐cell lymphoma and Burkitt lymphoma, is a poorly characterized entity. Therefore, we investigated cases of B‐UCL treated by the Nebraska Lymphoma Study Group (NLSG). We searched the NLSG registry for years 1985–2010 for cases of B‐UCL. Immunohistochemical stains and fluorescence in situ hybridization studies for MYC, BCL2 and BCL6 gene rearrangements were performed. Among the 39 cases studied, 54% were male and 46% were female, with a median age of 69 years. The majority of patients presented with advanced‐stage disease (62%) and had high (3–5) International Prognostic Index (IPI) scores (54%). The median overall survival (OS) was only 9 months and the 5‐year OS was 30%. Patients with low IPI scores (0–2) had a better survival than those with high scores (3–5). The cases were genetically heterogeneous and included 11 ‘double‐hit’ lymphomas with rearrangements of both MYC and BCL2 or BCL6. None of the immunohistochemical or genetic features was predictive of survival. This B‐cell lymphoma is a morphologically‐recognizable entity with a spectrum of genetic abnormalities. New and better treatments are needed for this aggressive lymphoma.</description><subject>Adult</subject><subject>Aged</subject><subject>BCL2</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Burkitt lymphoma</subject><subject>Burkitt Lymphoma - diagnosis</subject><subject>Burkitt Lymphoma - therapy</subject><subject>Combined Modality Therapy</subject><subject>Cytogenetic Analysis</subject><subject>Diagnosis, Differential</subject><subject>diffuse large B‐cell lymphoma</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Immunophenotyping</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Lymphoma, B-Cell - classification</subject><subject>Lymphoma, B-Cell - diagnosis</subject><subject>Lymphoma, B-Cell - therapy</subject><subject>Lymphoma, Large B-Cell, Diffuse - diagnosis</subject><subject>Lymphoma, Large B-Cell, Diffuse - therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>MYC</subject><subject>Neoplasm Staging</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>unclassifiable B‐cell lymphoma</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqN0cFqFDEYB_BQlHZbPfQFSi6CQqdNJtlk480WtUrBi56HL9kvbtrMzDbJsOzNFxD6jD6Js-62HqRgLoHkx_8L-RNyzNkZH9e5vVmc8VpIsUcmXKhpVXPJn5EJY0xXnMnZATnM-YYxLtiU75ODWqjxiqsJ-Xnx68e9wxhpXLfLRd_CKR06FyHn4APYiKd0FcqCeoQyJMw0dAVTi_MABanFskLs6Dx4P2SkEdJ3pP9kUujm1A7pNpTyePiW5jLM17T3VBjqIGN-QZ57iBlf7vYj8u3D-6-XV9X1l4-fLt9dV07WQlRCK-lmU4tSABjLrAJptFfWaCOUVEIzwLr22jqQXjCNzMgZOERUaDwXR-T1NneZ-rsBc2nakDcvhg77ITdcGGO40ux_qNIzbaScjvTNlrrU55zQN8sUWkjrhrNmU1QzFtX8KWq0J7vYwY6f-SgfmhnBqx2A7CD6BJ0L-a_TUhnBNu5861Yh4vrpic3F56vt6N8lAqx7</recordid><startdate>201307</startdate><enddate>201307</enddate><creator>Perry, Anamarija M.</creator><creator>Crockett, David</creator><creator>Dave, Bhavana J.</creator><creator>Althof, Pamela</creator><creator>Winkler, Lisa</creator><creator>Smith, Lynette M.</creator><creator>Aoun, Patricia</creator><creator>Chan, Wing C.</creator><creator>Fu, Kai</creator><creator>Greiner, Timothy C.</creator><creator>Bierman, Phillip</creator><creator>Gregory Bociek, Robert</creator><creator>Vose, Julie M.</creator><creator>Armitage, James O.</creator><creator>Weisenburger, Dennis D.</creator><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>201307</creationdate><title>B‐cell lymphoma, unclassifiable, with features intermediate between diffuse large B‐cell lymphoma and burkitt lymphoma: study of 39 cases</title><author>Perry, Anamarija M. ; Crockett, David ; Dave, Bhavana J. ; Althof, Pamela ; Winkler, Lisa ; Smith, Lynette M. ; Aoun, Patricia ; Chan, Wing C. ; Fu, Kai ; Greiner, Timothy C. ; Bierman, Phillip ; Gregory Bociek, Robert ; Vose, Julie M. ; Armitage, James O. ; Weisenburger, Dennis D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4233-3764c85be43aa9b0b6a497f6b9793646370ae22f7bca4f307e0948aceee6e9f13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>BCL2</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Burkitt lymphoma</topic><topic>Burkitt Lymphoma - diagnosis</topic><topic>Burkitt Lymphoma - therapy</topic><topic>Combined Modality Therapy</topic><topic>Cytogenetic Analysis</topic><topic>Diagnosis, Differential</topic><topic>diffuse large B‐cell lymphoma</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Immunophenotyping</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Lymphoma, B-Cell - classification</topic><topic>Lymphoma, B-Cell - diagnosis</topic><topic>Lymphoma, B-Cell - therapy</topic><topic>Lymphoma, Large B-Cell, Diffuse - diagnosis</topic><topic>Lymphoma, Large B-Cell, Diffuse - therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>MYC</topic><topic>Neoplasm Staging</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>unclassifiable B‐cell lymphoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Perry, Anamarija M.</creatorcontrib><creatorcontrib>Crockett, David</creatorcontrib><creatorcontrib>Dave, Bhavana J.</creatorcontrib><creatorcontrib>Althof, Pamela</creatorcontrib><creatorcontrib>Winkler, Lisa</creatorcontrib><creatorcontrib>Smith, Lynette M.</creatorcontrib><creatorcontrib>Aoun, Patricia</creatorcontrib><creatorcontrib>Chan, Wing C.</creatorcontrib><creatorcontrib>Fu, Kai</creatorcontrib><creatorcontrib>Greiner, Timothy C.</creatorcontrib><creatorcontrib>Bierman, Phillip</creatorcontrib><creatorcontrib>Gregory Bociek, Robert</creatorcontrib><creatorcontrib>Vose, Julie M.</creatorcontrib><creatorcontrib>Armitage, James O.</creatorcontrib><creatorcontrib>Weisenburger, Dennis D.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Perry, Anamarija M.</au><au>Crockett, David</au><au>Dave, Bhavana J.</au><au>Althof, Pamela</au><au>Winkler, Lisa</au><au>Smith, Lynette M.</au><au>Aoun, Patricia</au><au>Chan, Wing C.</au><au>Fu, Kai</au><au>Greiner, Timothy C.</au><au>Bierman, Phillip</au><au>Gregory Bociek, Robert</au><au>Vose, Julie M.</au><au>Armitage, James O.</au><au>Weisenburger, Dennis D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>B‐cell lymphoma, unclassifiable, with features intermediate between diffuse large B‐cell lymphoma and burkitt lymphoma: study of 39 cases</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2013-07</date><risdate>2013</risdate><volume>162</volume><issue>1</issue><spage>40</spage><epage>49</epage><pages>40-49</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><coden>BJHEAL</coden><abstract>Summary
B‐cell lymphoma, unclassifiable (B‐UCL), with features intermediate between diffuse large B‐cell lymphoma and Burkitt lymphoma, is a poorly characterized entity. Therefore, we investigated cases of B‐UCL treated by the Nebraska Lymphoma Study Group (NLSG). We searched the NLSG registry for years 1985–2010 for cases of B‐UCL. Immunohistochemical stains and fluorescence in situ hybridization studies for MYC, BCL2 and BCL6 gene rearrangements were performed. Among the 39 cases studied, 54% were male and 46% were female, with a median age of 69 years. The majority of patients presented with advanced‐stage disease (62%) and had high (3–5) International Prognostic Index (IPI) scores (54%). The median overall survival (OS) was only 9 months and the 5‐year OS was 30%. Patients with low IPI scores (0–2) had a better survival than those with high scores (3–5). The cases were genetically heterogeneous and included 11 ‘double‐hit’ lymphomas with rearrangements of both MYC and BCL2 or BCL6. None of the immunohistochemical or genetic features was predictive of survival. This B‐cell lymphoma is a morphologically‐recognizable entity with a spectrum of genetic abnormalities. New and better treatments are needed for this aggressive lymphoma.</abstract><cop>Oxford</cop><pub>Blackwell</pub><pmid>23600716</pmid><doi>10.1111/bjh.12343</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2013-07, Vol.162 (1), p.40-49 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1399916701 |
| source | MEDLINE; Wiley Journals; Wiley Online Library Free Content; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Aged BCL2 Biological and medical sciences Biomarkers, Tumor - genetics Biomarkers, Tumor - metabolism Burkitt lymphoma Burkitt Lymphoma - diagnosis Burkitt Lymphoma - therapy Combined Modality Therapy Cytogenetic Analysis Diagnosis, Differential diffuse large B‐cell lymphoma Female Hematologic and hematopoietic diseases Humans Immunophenotyping Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphoma, B-Cell - classification Lymphoma, B-Cell - diagnosis Lymphoma, B-Cell - therapy Lymphoma, Large B-Cell, Diffuse - diagnosis Lymphoma, Large B-Cell, Diffuse - therapy Male Medical sciences Middle Aged MYC Neoplasm Staging Treatment Outcome Tumors unclassifiable B‐cell lymphoma |
| title | B‐cell lymphoma, unclassifiable, with features intermediate between diffuse large B‐cell lymphoma and burkitt lymphoma: study of 39 cases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T10%3A28%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=B%E2%80%90cell%20lymphoma,%20unclassifiable,%20with%20features%20intermediate%20between%20diffuse%20large%20B%E2%80%90cell%20lymphoma%20and%20burkitt%20lymphoma:%20study%20of%2039%20cases&rft.jtitle=British%20journal%20of%20haematology&rft.au=Perry,%20Anamarija%20M.&rft.date=2013-07&rft.volume=162&rft.issue=1&rft.spage=40&rft.epage=49&rft.pages=40-49&rft.issn=0007-1048&rft.eissn=1365-2141&rft.coden=BJHEAL&rft_id=info:doi/10.1111/bjh.12343&rft_dat=%3Cproquest_cross%3E1367879445%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1367879445&rft_id=info:pmid/23600716&rfr_iscdi=true |